Powering Up T Cells: A New Path in Cancer Immunotherapy
en-GBde-DEes-ESfr-FR

Powering Up T Cells: A New Path in Cancer Immunotherapy


Researchers have discovered a way to make the immune system’s T cells significantly more effective at fighting cancer. By blocking a protein called Ant2, they were able to reprogram how these cells consume and generate energy—essentially rewiring their internal power supply. This shift makes T cells more active, resilient, and better at attacking tumors. The findings open the door to new treatments that could strengthen the body’s own immune response, offering a smarter, more targeted approach to cancer therapy.

A new study may pave the way for a new generation of cancer therapies—by training the body’s own immune system to work smarter and hit harder. Led by PhD student Omri Yosef and Prof. Michael Berger from the Faculty of Medicine at Hebrew University, in collaboration with Prof. Magdalena Huber of Philipps University of Marburg and Prof. Eyal Gottlieb of the University of Texas MD Anderson Cancer Center, the international team discovered that fine-tuning immune cells metabolism dramatically improves their ability to destroy cancer.

At the heart of the research is a powerful insight: when T cells—key players in the immune system—are forced to rewire how they convert energy, they become significantly more effective at identifying and attacking tumors.
“By disabling Ant2, we triggered a complete shift in how T cells produce and use energy,” explains Prof. Berger. “This reprogramming made them significantly better at recognizing and killing cancer cells.” In simpler terms, blocking this protein forces the immune cells to adapt their metabolism, turning them into stronger, faster, and more aggressive cancer fighters.

Published in Nature Communications, the study focuses on the mitochondria—the "metabolic hub" of cells. By deliberately disrupting a specific energy pathway inside T cells, the team essentially rewired the cells’ engines, creating a state of heightened readiness and potency. The altered T cells exhibited greater stamina, faster replication, and sharper targeting of cancerous threats.

Perhaps most importantly, the researchers showed that this metabolic rewiring can be triggered not only through genetic modifications but also with drugs—opening the door for potential clinical applications.

This discovery is part of a growing movement in cancer immunotherapy that focuses not only on guiding the immune system but upgrading its inner machinery. While more studies and clinical trials are needed, the implications of this breakthrough are promising: new treatments that harness the body’s own defenses, fine-tuned for peak performance.

“This work highlights how deeply interconnected metabolism and immunity truly are,” says Prof. Berger. “By learning how to control the power source of our immune cells, we may be able to unlock therapies that are both more natural and more effective.”

The research paper titled “Metabolic reprogramming driven by Ant2 deficiency augments T Cell function and anti-tumor immunity in mice” is now available in Nature Communications and can be accessed at https://www.nature.com/articles/s41467-025-59310-3
Researchers:
Omri Yosef1, Leonor Cohen-Daniel1, Oded Shamriz1, Zahala Bar-On1, Wajeeh Salaymeh1, Amijai Saragovi1, Ifat Abramovich2, Bella Agranovich2, Veronika Lutz3, Joseph Tam4, Anna Permyakova4, Eyal Gottlieb5, Magdalena Huber3 & Michael Berger1
Institutions:
1. The Institute for Medical Research Israel-Canada (IMRIC), Faculty of Medicine, The Hebrew University of Jerusalem
2. Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology
3. Institute of Systems Immunology, Philipps University of Marburg
4. Obesity and Metabolism Laboratory, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem
5. Department of Cancer Biology, University of Texas MD Anderson Cancer Center
Archivos adjuntos
  • Title: Tumor Size Under Different Treatment ConditionsDescription: This image displays tumors collected at the end of the experiment from three experimental groups: untreated controls, OT-I CD8+ T cell recipients without additional treatment, and those receiving OT-I CD8+ T cells followed by ATR therapy. The 5 mm scale bar highlights visible differences in tumor volume. Growth was measured daily starting on day 17 post-implantation to evaluate treatment effectiveness.Credit: The authors
Regions: Middle East, Israel
Keywords: Health, Medical, Science, Life Sciences

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonios

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Trabajamos en estrecha colaboración con...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2025 by DNN Corp Terms Of Use Privacy Statement